| Health / Medical Topics |
HDAC Inhibitor CHR-2845
A hydroxamic acid-derived histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. CHR-2845 inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in chromatin remodeling, inhibition of tumor oncogene transcription, inhibition of tumor cell division, and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins; this agent may specifically target HDACs in cells of the monocyte-macrophage lineage. (NCI Thesaurus)
YOU MAY ALSO LIKE
A histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. CG200745 inhibits the catalytic activity of HDAC, resulting in an accumulation of highly…
An orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic…
A substance that causes a chemical change that stops tumor cells from dividing. HDAC inhibitors are being studied in the treatment of…
An enzyme that removes a small molecule called an acetyl group from histones (proteins found in chromosomes). This changes the way the…
Bipartite DNA binding domain containing a homeo domain and a leucine zipper.
The NCI term type designation for a header term.
